E-LIB Suche - Ergebnisse für: Nasta, S.

1

Outcomes of diffuse large/high grade B cell lymphoma patien..:

Landsburg, D. J. ; Nasta, S. D. ; Svoboda, J....
Hematological Oncology. 41 (2023) S2 - p. 448-449 , 2023

Link: https://doi.org/10.1002/..

2

Brentuximab vedotin (BV) + AVD for newly diagnosed classic ..:

Bowers, J. T. ; Anna, J. ; Bair, S. M....
Hematological Oncology. 41 (2023) S2 - p. 359-360 , 2023

Link: https://doi.org/10.1002/..

3

FOURTH GENERATION HUCART19‐IL18 PRODUCES DURABLE RESPONSES ..:

Svoboda, J. ; Landsburg, D. L. ; Chong, E. A....
Hematological Oncology. 41 (2023) S2 - p. 35-37 , 2023

Link: https://doi.org/10.1002/..

4

Predictors of long‐term survival outcomes following receipt..:

Landsburg, D. J. ; Nasta, S. D. ; Svoboda, J....
Hematological Oncology. 41 (2023) S2 - p. 445-447 , 2023

Link: https://doi.org/10.1002/..

5

Outcomes with bendamustine lymphodepletion and brexucabtage..:

Chong, E. A. ; Gerson, J. N. ; Nasta, S. D....
Hematological Oncology. 41 (2023) S2 - p. 528-529 , 2023

Link: https://doi.org/10.1002/..

6

Combination of everolimus and itacitinib in patients with H..:

Svoboda, J. ; Landsburg, D. L. ; Nasta, S. D....
Hematological Oncology. 41 (2023) S2 - p. 594-595 , 2023

Link: https://doi.org/10.1002/..

7

BENDAMUSTINE LYMPHODEPLETION TRIGGERS REDUCED INFLAMMATORY ..:

Ghilardi, G. ; Paruzzo, L. ; Svoboda, J....
Hematological Oncology. 41 (2023) S2 - p. 201-201 , 2023

Link: https://doi.org/10.1002/..

8

Patient‐ versus clinician‐reported symptoms in the POLARIX ..:

Thompson, C. A. ; Mehta‐Shah, N. ; Flowers, C....
Hematological Oncology. 41 (2023) S2 - p. 414-416 , 2023

Link: https://doi.org/10.1002/..

9

Cytokine Release Syndrome and Neurotoxicity after Chimeric ..:

Yegya-Raman, N. ; Wright, C.M. ; Zhang, S....
International Journal of Radiation Oncology*Biology*Physics. 114 (2022) 3 - p. S84-S85 , 2022

Link: https://doi.org/10.1016/..

10

SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE..:

Levy, M. Y. ; Grudeva‐Popova, Z. ; Trneny, M....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

11

Radiation Therapy (RT)-Based Salvage Therapy for Classical ..:

Manjunath, S.H. ; Larose, M.I. ; Carpenter, M....
International Journal of Radiation Oncology*Biology*Physics. 111 (2021) 3 - p. e305 , 2021

Link: https://doi.org/10.1016/..

12

TIME‐TO‐RESPONSE FOR PATIENTS WITH RELAPSED/REFRACTORY AGGR..:

Hughes, M. E. ; Nasta, S. D. ; Gerson, J. N....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

13

PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WI..:

Mato, A.R. ; Svoboda, J. ; Luning Prak, E.T....
Hematological Oncology. 37 (2019) S2 - p. 119-120 , 2019

Link: https://doi.org/10.1002/..

14

CD19‐DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFR..:

Chong, E.A. ; Svoboda, J. ; Nasta, S.D....
Hematological Oncology. 37 (2019) S2 - p. 137-138 , 2019

Link: https://doi.org/10.1002/..

15

EVITA: PHASE I/II STUDY OF EVEROLIMUS PLUS ITACITINIB IN RE..:

Svoboda, J. ; Barta, S. ; Nasta, S....
Hematological Oncology. 37 (2019) S2 - p. 573-574 , 2019

Link: https://doi.org/10.1002/..